shutterstock_1569359980_sundry-photography

shutterstock_1569359980_Sundry Photography

11 January 2024Big PharmaLiz Hockley

EU: Finland liability regime 'compatible' in big pharma feud

Case concerns a supplementary protection certificate granted to Gilead by Finland’s Patent Office for a HIV drug | CJEU judges contradict AG opinion on whether a Finnish regime is at odds with an EU directive.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Fed Circ injects new life into Mylan dispute

7 November 2023 Appeals court faults lower court’s claim construction and its reliance on intrinsic evidence alone | Court emphasises that extrinsic evidence is needed in litigation over heart disease drug.

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

More on this story

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

Fed Circ injects new life into Mylan dispute

7 November 2023 Appeals court faults lower court’s claim construction and its reliance on intrinsic evidence alone | Court emphasises that extrinsic evidence is needed in litigation over heart disease drug.

More on this story

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

Fed Circ injects new life into Mylan dispute

7 November 2023 Appeals court faults lower court’s claim construction and its reliance on intrinsic evidence alone | Court emphasises that extrinsic evidence is needed in litigation over heart disease drug.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent